重组人干扰素α2b氧驱雾化吸入佐治毛细支气管炎疗效及安全性观察  

Efficacy and safety of recombinant human interferon α2b oxygen inbreathe for bronchiolitis

作　　者：毛庆东[1] MAO Qingdong(Pediatrics of Wuhu Hospital of Traditional Chinese Medicine, Wuhu 241002, Anhui, China)

机构地区：[1]安徽省芜湖市中医医院儿科

出　　处：《中国临床药理学与治疗学》2018年第8期927-931,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:评价重组人干扰素α2b氧驱雾化吸入佐治毛细支气管炎的有效性及安全性。方法:将86例毛细支气管炎患儿分成对照组及观察组,每组43例。两组一般治疗相同,观察组加用重组人干扰素α2b氧驱雾化吸入。疗程结束后比较两组治疗总有效率、临床症状体征改善及住院时间、不良反应及血常规和生化指标。结果:观察组患儿总有效率(95.35%)明显高于对照组(83.72%)(P<0.05);观察组临床症状、体征持续时间及住院天数均小于对照组(P<0.05);在血常规、血生化指标及不良反应发生方面,两组患儿差异不明显(P>0.05)。结论:重组人干扰素α2b氧驱雾化吸入佐治毛细支气管炎能提高临床有效率,缩短住院时间,安全性较好。AIM： To evaluate the efficacy and safety of recombinant human interferon α2b oxygen inbreathe for bronchiolitis. METHODS： Eighty-six children with bronchiolitis were divided into control group and observation group,with 43 cases in each group. The two groups were generally treated in the same way,while the observation group was additionally inhaled with recombinant human interferon α2b oxygen drive. At end of the treatment period,the total effective rate,clinical symptoms and signs,hospital stay,adverse reactions,and blood routine and biochemical indexes were observed and compared between the two groups. RESULTS： The total effective rate（95. 35%） of the observation group was significantly higher than that of the control group（83. 72%）（P〈0.05）; the duration of clinical symptoms and signs of the treatment group was less than those of the control group（P〈0.05）; There was no significant difference between the two groups of children in the blood routine,blood biochemical indicators and regarding adverse reactions（P〉0.05）. CONCLUSION： Recombinant human interferon α2b oxygen inbreathe can improve the clinical cure rate,shorten the hospital stay of bronchiolitis with safety.

关 键 词：重组人干扰素Α2B 氧驱雾化吸入 毛细支气管炎 疗效 

分 类 号：R725.6[医药卫生—儿科]